Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis
© Beigelman et al. 2010
Received: 2 March 2010
Accepted: 30 June 2010
Published: 30 June 2010
Skip to main content
© Beigelman et al. 2010
Received: 2 March 2010
Accepted: 30 June 2010
Published: 30 June 2010
Viral bronchiolitis is the leading cause of hospitalization in young infants. It is associated with the development of childhood asthma and contributes to morbidity and mortality in the elderly. Currently no therapies effectively attenuate inflammation during the acute viral infection, or prevent the risk of post-viral asthma. We hypothesized that early treatment of a paramyxoviral bronchiolitis with azithromycin would attenuate acute and chronic airway inflammation.
Mice were inoculated with parainfluenza type 1, Sendai Virus (SeV), and treated daily with PBS or azithromycin for 7 days post-inoculation. On day 8 and 21 we assessed airway inflammation in lung tissue, and quantified immune cells and inflammatory mediators in bronchoalveolar lavage (BAL).
Compared to treatment with PBS, azithromycin significantly attenuated post-viral weight loss. During the peak of acute inflammation (day 8), azithromycin decreased total leukocyte accumulation in the lung tissue and BAL, with the largest fold-reduction in BAL neutrophils. This decreased inflammation was independent of changes in viral load. Azithromycin significantly attenuated the concentration of BAL inflammatory mediators and enhanced resolution of chronic airway inflammation evident by decreased BAL inflammatory mediators on day 21.
In this mouse model of paramyxoviral bronchiolitis, azithromycin attenuated acute and chronic airway inflammation. These findings demonstrate anti-inflammatory effects of azithromycin that are not related to anti-viral activity. Our findings support the rationale for future prospective randomized clinical trials that will evaluate the effects of macrolides on acute viral bronchiolitis and their long-term consequences.
Viral bronchiolitis is the most common acute infection of the lower respiratory tract in infancy, and is most often caused by the paramyxoviruses, especially respiratory syncytial virus (RSV). RSV will infect 95% of children by the age of 2 , and up to 3% of infected children will develop a severe bronchiolitis requiring hospitalization . The rate of admissions has doubled in the past 2 decades ; as a result, severe RSV bronchiolitis is now the leading cause of hospitalization in infants younger the age of 1 year . Chronic respiratory symptoms are common after severe RSV bronchiolitis, with about 40% of hospitalized children eventually developing asthma [5–8]. The development of asthma following RSV infection appears to be related to the severity of the initial infection . RSV infection is not limited to children and contributes significantly to morbidity and mortality in the elderly population . These findings suggest that attenuating the acute viral infection may be an effective strategy to attenuate the acute and long-term consequences of viral bronchiolitis.
No specific therapies are currently recommended for severe RSV bronchiolitis . Ideally a beneficial pharmacologic agent would reduce acute morbidity as well as modify the anti-viral host response to avert the subsequent development of asthma. One class of potentially useful therapeutic agents is the macrolide antibiotics, since they possess distinct anti-inflammatory properties in addition to their antimicrobial effects [12–25]. Two clinical studies have evaluated macrolide treatment during severe RSV bronchiolitis in children, but these studies have yielded conflicting results [26, 27]. Therefore, definitive conclusions regarding the usefulness of macrolides as a treatment of viral-bronchiolitis cannot be made at this time.
To examine the anti-inflammatory properties of macrolides in a high fidelity animal model of human RSV bronchiolitis, we tested the ability of azithromycin to modulate a well-characterized viral bronchiolitis model using a mouse parainfluenza type I virus, referred to as Sendai virus (SeV) [28, 29]. SeV replicates at high efficiency in the mouse lung and results in an acute viral bronchiolitis, and chronic airway inflammation that persists for at least one year following viral inoculation [28, 29]. We hypothesized that treatment of mouse SeV bronchiolitis with azithromycin during the acute infection would attenuate early airway inflammation, and also decrease the chronic post-viral pathologic abnormalities, such as immune cell accumulation and the mediators that drive these processes.
C57BL/6J female mice were purchased from the Jackson Laboratory (Bar Harbor, ME). All mice were bred and housed under specific pathogen-free conditions at Washington University School of Medicine where sentinel mice (pathogen free ICN-strain) exhibited no serologic or histologic evidence of exposure to 15 murine pathogens (including SeV). Before performing these in vivo experiments, we investigated whether our colony of mice were actively infected or colonized with bacteria in the trachea and lungs. We obtained tracheal swabs and tissue samples from both lungs, from 5 mice, and plated them on tryptic soy agar plates supplemented with 5% sheep blood, incubated for 48 hours at 37°C and no colonies were identified. To determine if our colony of mice had serologic evidence of prior Mycoplasma pulmonis exposure, serum was collected for indirect ELISA using Mycoplasma pulmonis antigen-coated plates according to manufacturer's recommendations (Charles River Laboratories, Wilmington, MA). These results were negative for infection as previously included in our prior manuscript . In addition, we have tested our SeV stock for bacterial contamination by streaking the viral stock on tryptic soy agar plates supplemented with 5% sheep blood followed by incubated for 48 hours at 37°C. No colonies were identified. The Institutional Animal Use and Care Committee of Washington University School of Medicine approved all animal experiments.
Mice were treated daily with subcutaneous azithromycin (50 mg/kg dissolved in 100 μL sterile PBS, purchased from Pfizer Pharmaceuticals, Dublin, Ireland), from day 0 (one hour after SeV inoculation) through day 7 post-viral inoculation. Mice that were treated with subcutaneous 100 μL sterile PBS served as a control for the azithromycin treatment. Azithromycin dose was determined based on our previous pharmacokinetic studies  which demonstrated that daily subcutaneous treatment of mice with azithromycin (50 mg/kg) produced serum levels similar to those observed in humans treated with the recommended azithromycin dose. Overall, a higher dosage of azithromycin is required in mice than humans due to more rapid liver metabolism in mice, resulting in an elimination half-life of 2.3 hours compared to 68 hours in humans [34, 35].
BAL and lung tissue harvest were performed as previously described [29–32]. Two blinded observers determined the BAL immune cell differential using standard light microscopy criteria as described previously [30, 31]. BAL inflammatory mediators were analyzed using a multiplex flow-cytometry based assay according to manufacturer's recommendations (Bio-Rad Laboratories) and as previously described [30, 31]. The detection limit for the Bio-plex mouse cytokine 23-plex panel (Bio-Rad) is: IL-1α - 2 pg/ml; IL-1β - 2 pg/ml; IL-2 - 3 pg/ml; IL-3 - 2 pg/ml; IL-4 - 3 pg/ml; IL-5 - 2 pg/ml; IL-6 - 2 pg/ml; IL-9 - 15 pg/ml; IL-10 - 2 pg/ml; IL-12 (p40) - 2 pg/ml; IL-12 (p70) - 4 pg/ml; IL-13 - 9 pg/ml; IL-17 - 1 pg/ml; eotaxin - 148 pg/ml; G-CSF - 1 pg/ml; GM-CSF - 7 pg/ml; IFN-γ - 6 pg/ml; KC - 3 pg/ml; CCL2/JE - 14 pg/ml; CCL3/MIP-1β - 24 pg/ml; CCL4/MIP-1ί - 2 pg/ml; CCL5/RANTES - 5 pg/ml; and TNF-α - 6 pg/ml.
Lung sections were stained with hematoxylin and eosin (H&E) and Periodic Acid-Schiff (PAS) [30, 31]. Quantification of mucus producing cells was performed by counting the number of airway cells that stained with PAS positive cells and using a PAS score as previously described [30, 36, 37]. Peripheral blood leukocyte counts were performed using an automated veterinary hematologic analyzer with a pre-programmed murine calibration mode (Hemavet 950FS, Drew Scientific, Waterbury, CT) as previously described .
The quantity of Sendai virus-specific RNA was determined from whole lung using a TaqMan one-step fluorogenic RT-PCR reaction according to the manufacturer's recommendation (Applied Biosystems, Foster City, CA) [29, 31]. Lung tissue was placed in RNA Later (Applied Biosystems), homogenized with stainless steel beads for 3 min (Biospect Products Inc., Bartlesville, OK), and column purified with an RNeasy mini kit according to the manufacturer's recommendations (Qiagen, Alencia, CA). Duplicate serial 10-fold dilutions of total RNA from Sendai-infected lung tissue underwent one-step fluorogenic RT-PCR for detection of Sendai virus nucleocapsid protein transcripts (upstream primer 5'-TCCACCCTGAGGAGCAGG-3'; downstream primer 5'-ACCCGGCCATCGTGAACT-3'; probe 5'-6FAM-TGGCAGCAAAGCAAAGGGTCTGGA-TAMRA-30) and murine GAPDH specific RNA (proprietary primer/probe combination, Applied Biosystems; #MM99999915G1) to construct standard curves. Sendai values were calculated as the mean of duplicate samples from reactions with a cycle threshold between 20 and 25 and final results were normalized to GAPDH and reported as the Sendai/GAPDH ratio.
Means from multiple groups (BAL cell counts and inflammatory mediator concentrations on day 8) were analyzed for statistical significance using a one-way analysis of variance (ANOVA) and post hoc comparison to identify significant differences between specific groups. An independent group's t-test was used to compare means from two groups (BAL cell counts and inflammatory mediator concentrations on day 21). The Mann-Whitney test was used to compare the lung PAS scores (an ordinal variable). The significance level for all tests was 0.05. Data were analyzed using SPSS 15 software (Chicago, IL).
To determine if azithromycin could confer anti-inflammatory properties in a mouse model of viral bronchiolitis, we inoculated mice on day 0 with SeV (5,000 egg infectious dose 50%, 5 K) and treated the mice daily with azithromycin or PBS from day 0 to day 7 (Figure 1A). Mice treated with azithromycin had attenuated weight loss compared to PBS treated mice, with significant differences observed on days 3 through 9 post-inoculation (Figure 1B). We noted a trend toward lower mortality in the azithromycin treated mice (Figure 1C): 23/23 mice survived in the azithromycin group versus 21/23 in the control group (p = 0.12). To assess whether azithromycin treatment would be beneficial using a higher infectious dose, we performed an experiment using a lethal infectious dose of virus (50,000 egg infectious dose 50%, 50 K). Treatment of this lethal infection with azithromycin did not significantly alter weight loss, overall survival or delay the time of death compared to treatment with PBS (N = 5 in each cohort). These results demonstrated that azithromycin treatment, in the 5 K infectious dose, attenuated some clinical features of the severity of the acute viral bronchiolitis. Therefore, we next sought to characterize the impact of azithromycin treatment on lung inflammation.
This study demonstrated that azithromycin possessed beneficial anti-inflammatory properties in a mouse model of paramyxoviral bronchiolitis. Azithromycin treatment improved the course of acute disease, evidenced by decreased weight loss and attenuated accumulation of BAL inflammatory cells and chemokines. Although not statistically significant, we noted a trend toward lower mortality in the azithromycin treated mice. We also observed that early azithromycin treatment was associated with modulation of certain features of the chronic post-viral inflammatory phase. To the best of our knowledge, this is the first study to demonstrate the beneficial effects of azithromycin in a mouse model of viral bronchiolitis and suggests this drug may also have beneficial effects in human bronchiolitis.
Our results are in agreement with a previous study by Sato and colleagues, who investigated the effect of erythromycin treatment using an in vivo model of influenza pneumonia . That study showed that erythromycin treatment in mice resulted in improved survival, decreased weight loss, and attenuated airway inflammation. Our results extend those findings by demonstrating that a clinically better tolerated macrolide displayed anti-inflammatory properties in a different viral infection model (i.e., a parainfluenza viral bronchiolitis vs. influenza pneumonia). In addition, we demonstrated that treatment of the acute inflammation is associated with attenuation of the chronic post-viral inflammatory phase.
Our results revealed that azithromycin had no effect on SeV viral kinetics in the lung tissue at day 5 and 8 post-viral inoculation, time points that corresponded to the peak of viral load in the lungs and virus clearance respectively . Accordingly, in this case we conclude that azithromycin has anti-inflammatory, but no direct in vivo anti-viral properties. This observation agrees with the previously mentioned report, in which erythromycin treatment did not alter influenza viral kinetics . Although weight loss is attenuated and viral clearance is not compromised by treatment with azithromycin, it remains unclear how azithromycin or other macrolides would alter additional clinical outcomes of a human viral infection such as nasal congestion, nasal discharge, and cough as we have not developed techniques to quantitate these in the mouse. We do note that a recent study found that macrolide antibiotics inhibited RSV infection in isolated human tracheal epithelial cells . These apparently conflicting results could be related to differences between in vivo and in vitro viral infection models, use of different paramyxoviruses, or to different dosing regimens and pharmacologic properties of the drugs.
During the peak inflammatory response, azithromycin treatment attenuated cellular influx in the lung tissue and BAL. Decreased cellular influx in site of inflammation is consistent with previous reports in other inflammatory models in which macrolides attenuated neutrophilic inflammation induced by inhaled LPS [41, 42] or intratracheal P. aeruginosa infection . The effect of azithromycin, in our viral bronchiolitis model, does not appear to be neutrophil-specific since the accumulation of macrophages and lymphocytes were also attenuated. In previous work, we demonstrated that azithromycin had the most profound effect on eosinophils in an in vivo allergic model of airway inflammation . Taken together, these observations suggest that macrolides possess broad anti-inflammatory properties that can attenuate the accumulation of multiple cell types in various airway inflammatory models.
One limitation of this study is the initiation of azithromycin treatment on the day of infection. Another limitation is that we did not test for a beneficial treatment effect of azithromycin on other respiratory viruses, such as RSV. RSV is a human pathogen and in our experience RSV infection of mice results in pneumonia rather then bronchiolitis. We have found that SeV replicates at high efficiency in the mouse lung and results in acute inflammation of the small airways (i.e., bronchiolitis) that better mimics human bronchiolitis. Since we have not tested for a beneficial treatment effect of azithromycin on RSV infection it is difficult to compare our results to previous studies that modulated the host immune response by blocking the CX3C chemokine activity of the G protein of RSV [44–46]. Future studies will be required to determine if different treatment regimens, such as initiation of treatment a few days after inoculation or alternate dosing regimens would result in a similar beneficial treatment effect on SeV as well as other respiratory viruses.
Although the precise biochemical mechanisms responsible for the anti-inflammatory effects of macrolides are not defined, this family of drugs can inhibit multiple cellular processes involved in an inflammatory response. For example, macrolides have been shown to inhibit neutrophil chemotaxis, leukocyte-epithelial cell adhesion, cytokine secretion and cytokine-dependent intracellular signaling [43, 47]. In this regard, macrolides block NF-κB and AP-1 dependent gene transcription of inflammatory mediators [42, 48, 49]. Thus, additional studies will be required to further define the precise cellular mechanisms responsible for the anti-inflammatory effects of azithromycin and to determine the optimal dosing regimens required to attenuate both the acute and chronic post-viral inflammatory phenotypes.
Previous clinical studies have shown that macrolides are beneficial in the treatment of inflammatory airway diseases such as diffuse panbronchiolitis , cystic fibrosis , and asthma [15–25]. Two previous studies investigated the effects of macrolide treatment in children hospitalized with RSV bronchiolitis [26, 27]. Tahan et al.  revealed that a 21 day course of clarithromycin treatment reduced length of hospital stay, the duration of additional treatments (supplemental oxygen, intravenous fluids and bronchodilators) and the day 21 concentrations of IL-4, IL-8 and eotaxin in the serum. However, this study was limited by a relatively small sample size (n = 21). In a recent larger study, Kneyber et al. found that azithromycin treatment did not improve the early disease course in infants hospitalized with RSV bronchiolitis . This study, although important, had two main limitations that may have obscured any potential benefits of the macrolide. First, the researchers designed an equivalence study based on the assumption that a difference less than ± 49.4 hours (approximately ± 2 days) in length of hospitalization would be considered as equivalence (i.e., no benefit for treatment). Therefore, this study was not powered to detect smaller differences in length of hospitalization. Second, the researchers recruited only 71% of the required study population that was determined based on their power analysis. This early termination of the trial prevents definitive conclusions.
The current study highlights the importance of measuring macrolide-dependent effects during the early phase of the viral infection as well as the late phase. In addition we have identified certain growth factors and chemokines (i.e., G-CSF, CCL2, CCL4, CCL5, and CXCL1) that could be tracked to establish a beneficial treatment effect. Accordingly, when planning a human study we feel early and long-term follow-up of clinical and biochemical endpoints should be included in the study design.
Our study revealed that treatment of mouse SeV bronchiolitis with azithromycin during the acute infection would attenuate acute and chronic airway inflammation, and also decrease the chronic post-viral pathologic abnormalities. However, we do not recommend the off-label use of azithromycin during RSV infection until additional prospective randomized clinical trials support its use since excessive use of macrolides has correlated with increased prevalence of macrolide-resistant organisms such as Streptococcus pneumonia .
Our results extend previous findings obtained in different in vivo models by demonstrating that azithromycin possessed anti-inflammatory properties in an in vivo model of viral bronchiolitis. We found that early treatment during viral infection is associated with attenuation of acute and chronic airway inflammation. Azithromycin treatment improved the course of acute disease, evidenced by decreased weight loss and attenuated accumulation of BAL inflammatory cells and chemokines. Our data revealed that early azithromycin treatment also modulates the chronic post-viral inflammatory phase. These results support the rationale for future prospective randomized clinical trials that will evaluate the effects of macrolides on acute viral bronchiolitis and their long-term consequences.
Analysis of Variance
Glyceraldehyde 3-Phosphate Dehydrogenase
Hematoxylin and Eosin
Respiratory Syncytial Virus
This work was supported by the National Institutes of Health [NIH R01-HL083894].
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.